2013 Fiscal Year Final Research Report
Development of a novel oral therapeutic HCV vaccine using bifidobacterium displaying antigen
| Project/Area Number |
23591475
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Infectious disease medicine
|
|---|
| Research Institution | Kobe University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
HOTTA Haku 神戸大学, 医学研究科, 教授 (40116249)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
KATAYAMA Takane 石川県立大学, 生物資源環境学部, 教授 (70346104)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Keywords | 慢性C型肝炎 / 経口ワクチン / ビフィズス菌 |
|---|
| Research Abstract |
More than 170 million people worldwide are chronic HCV (Hepatitis C virus) carriers. A combination of pegylated interferon-alpha with ribavirin, the standard treatment for HCV infection, has been effective in fewer than 50 percent of patients infected with HCV genotype 1. A strong T cell response against the nonstructural protein 3 (NS3) is important for recovery from acute HCV infection, and an early multi-specific CD4 helper and CD8 cytotoxic T cell response is critical for HCV clearance. In the present study, we successfully constructed a genetically modified Bifidobacterium longum displaying recombinant HCV-NS3 peptides containing some CD4 and CD8 epitopes located in the HCV-NS3 region as an oral vaccine against chronic HCV infection. The oral administration of this vaccine could induce NS3-specific immune responses in mice through intestinal mucosal immunity.
|
